A look at current literature and work by a statewide initiative can motivate development of policies that help respond to unrepresented patients’ needs.
AMA J Ethics. 2019;21(7):E611-616. doi:
10.1001/amajethics.2019.611.
When patients are unable to express their wishes and do not have surrogates or advance directives, which and whose values should inform decision making for them? We discuss ethical complexities of caring for unrepresented patients.
William M. Hart, MD, Patricia Doerr, MD, Yuxiao Qian, MD, and Peggy M. McNaull, MD
When errors happen, too often clinicians are at odds with each other about how to respond to a patient or a patient’s loved ones after that patient suffers harm.
AMA J Ethics. 2020;22(4):E298-304. doi:
10.1001/amajethics.2020.298.
How would gathering preclinical data and improving research infrastructure facilitate clearer definitions of “population vulnerability” and “risk acceptability”?
AMA J Ethics. 2020;22(1):E43-49. doi:
10.1001/amajethics.2020.43.
Aminu Yakubu, Nchangwi Syntia Munung, and Jantina De Vries, PhD
African cancer research is embedded in underresourced health care infrastructures, illuminating ethical questions about benefit sharing and governance.
AMA J Ethics. 2020;22(2):E156-163. doi:
10.1001/amajethics.2020.156.